Intravenous immunoglobulin for cranial polyneuropathy associated with Campylobacter jejuni infection.
This study reports the efficacy of i.v. immunoglobulin in a patient with cranial polyneuropathy resulting from Campylobacter jejuni infection who had high titers of serum IgG antibodies against gangliosides GD1a and GT1b in the acute phase. Treatment with i.v. immunoglobulin (400 mg/kg/day x 5 days) led to rapid partial resolution of his neurologic manifestations, but complete recovery was not obtained until 6 months later. The present case suggests that i.v. immunoglobulin therapy prevents further progression of the disease but that it may not shorten the clinical course of cranial polyneuropathy in some cases associated with Campylobacter jejuni infection.
Wakamoto
H
H
Department of Pediatrics, Ehime Prefecture Niihama Hospital, Ehime, Japan.
Ohta
M
M
Nakano
N
N
Tagawa
M
M
Shiraishi
T
T
D000208:Acute Disease; D000293:Adolescent; D000907:Antibodies, Bacterial / Q000097:blood; D002169:Campylobacter Infections / Q000175:diagnosis* / Q000276:immunology; D016123:Campylobacter jejuni / Q000276:immunology / Q000302:isolation & purification*; D003389:Cranial Nerve Diseases / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D005677:G(M1) Ganglioside / Q000031:analogs & derivatives* / Q000276:immunology; D005732:Gangliosides / Q000276:immunology; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D016896:Treatment Outcome
D000907:Antibodies, Bacterial; D005732:Gangliosides; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D016756:Immunoglobulins, Intravenous; C064020:ganglioside GD1alpha; C033851:ganglioside, GD1b; D005677:G(M1) Ganglioside